X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
male (72) 72
female (71) 71
index medicus (67) 67
middle aged (66) 66
adult (65) 65
aged (63) 63
hematology (63) 63
chemotherapy (36) 36
oncology (32) 32
stem cells (32) 32
treatment outcome (32) 32
transplantation (29) 29
transplantation, autologous (28) 28
adolescent (24) 24
cancer (23) 23
retrospective studies (20) 20
analysis (16) 16
lymphomas (16) 16
prognosis (16) 16
prospective studies (16) 16
young adult (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
colony-stimulating factor (15) 15
disease-free survival (15) 15
stem cell transplantation (15) 15
c-reactive protein (14) 14
care and treatment (14) 14
septic shock (14) 14
severe sepsis (14) 14
autologous stem cell transplantation (13) 13
blood (13) 13
plus g-csf (13) 13
multiple-myeloma (12) 12
non-hodgkins-lymphoma (12) 12
outcome (12) 12
plerixafor (12) 12
biomarkers - blood (11) 11
hematopoietic stem cell mobilization - methods (11) 11
multiple myeloma (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
bacteremia (10) 10
follow-up studies (10) 10
immunology (10) 10
leukemia (10) 10
medical and health sciences (10) 10
medicin och hälsovetenskap (10) 10
neutropenia - complications (10) 10
recurrence (10) 10
sepsis (10) 10
survival analysis (10) 10
therapy (10) 10
antineoplastic agents - therapeutic use (9) 9
combined modality therapy (9) 9
cyclophosphamide (9) 9
cyclophosphamide - administration & dosage (9) 9
finland (9) 9
guidelines (9) 9
hematopoietic stem cell transplantation (9) 9
high-dose therapy (9) 9
lymphoma, non-hodgkin - therapy (9) 9
patients (9) 9
bone marrow (8) 8
bone-marrow-transplantation (8) 8
febrile neutropenia (8) 8
fever (8) 8
hematopoietic stem (8) 8
lymphoma (8) 8
mortality (8) 8
multiple myeloma - therapy (8) 8
neutropenic fever (8) 8
non-hodgkin's lymphomas (8) 8
risk factors (8) 8
survival (8) 8
survival rate (8) 8
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
count recovery (7) 7
cyclophosphamide - therapeutic use (7) 7
doxorubicin - administration & dosage (7) 7
health aspects (7) 7
hematopoietic stem cell mobilization (7) 7
hematopoietic stem cell transplantation - methods (7) 7
hematopoietic stem cells (7) 7
immunohistochemistry (7) 7
infection (7) 7
infectious diseases (7) 7
medicine, research & experimental (7) 7
procalcitonin (7) 7
risk (7) 7
stem-cell transplantation (7) 7
time factors (7) 7
transplantation, homologous (7) 7
animals (6) 6
antineoplastic agents - adverse effects (6) 6
autologous transplantation (6) 6
clinical medicine (6) 6
doxorubicin - therapeutic use (6) 6
finland - epidemiology (6) 6
hematologic neoplasms - complications (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Pathology, ISSN 0021-9746, 04/2019, Volume 72, Issue 4, pp. 316 - 321
AimsOxidative stress markers and antioxidant enzymes have previously been shown to have prognostic value and associate with adverse outcome in patients with... 
nrf2 | diffuse large B-cell lymphoma | keap1 | nrf1 | bach1 | KEAP1 | OXIDATIVE STRESS | ACTIVATION | PATHOLOGY | NRF2 INHIBITOR | EXPRESSION | Immunohistochemistry | Antineoplastic Agents, Immunological - administration & dosage | Predictive Value of Tests | Prednisolone - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cytoplasm - pathology | Young Adult | Cell Nucleus - pathology | Lymphoma, Large B-Cell, Diffuse - chemistry | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Rituximab - adverse effects | Cytoplasm - chemistry | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | NF-E2-Related Factor 1 - analysis | Risk Assessment | Biomarkers, Tumor - analysis | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Kelch-Like ECH-Associated Protein 1 - analysis | Lymphoma, Large B-Cell, Diffuse - mortality | Rituximab - administration & dosage | Antineoplastic Agents, Immunological - adverse effects | Basic-Leucine Zipper Transcription Factors - analysis | NF-E2-Related Factor 2 - analysis | Vincristine - adverse effects | Aged | Cell Nucleus - chemistry | Neoplasm Staging | Doxorubicin - adverse effects | Medical research | Enzymes | Oxidative stress | Transcription factors | Disease | Lung cancer | Colorectal cancer | Nervous system | Metastasis | Gene expression | Patients | Cancer therapies | Antioxidants | Proteins | Survival analysis | Hospitals | Medical prognosis | Epigenetics | Lymphomas | Original | 1506
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 25, pp. 3093 - 3099
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 07/2019, Volume 60, Issue 9, pp. 2115 - 2121
Lymphomas constitute the second most common indication for autologous hematopoietic cell transplantation (AHCT). Graft infusion is followed by a rapid... 
immune recovery | Lymphoma | autologous hematopoietic cell transplantation | outcome | MULTIPLE-MYELOMA | NATURAL-KILLER-CELLS | AUTO-SCT | PROGRESSION-FREE SURVIVAL | AUTOGRAFT LYMPHOCYTE | ONCOLOGY | HIGH-DOSE THERAPY | COUNT RECOVERY | PLERIXAFOR INJECTION | NON-HODGKIN-LYMPHOMA | HEMATOLOGY | PREDICTS SUPERIOR SURVIVAL
Journal Article
Transfusion, ISSN 0041-1132, 04/2012, Volume 52, Issue 4, pp. 906 - 914
Journal Article
Transfusion, ISSN 0041-1132, 05/2013, Volume 53, Issue 5, pp. 1024 - 1032
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 06/2014, Volume 14, Issue 6, pp. 851 - 861
Journal Article
Hematological Oncology, ISSN 0278-0232, 04/2019, Volume 37, Issue 2, pp. 136 - 142
Diffuse large B‐cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R‐CHOP. The current 5‐year overall survival is 60%... 
treatment | DLBCL | elderly | RISK-FACTORS | CYCLOPHOSPHAMIDE | R-CHOP | REGIMEN | CARDIOTOXICITY | CHEMOTHERAPY | PATIENTS AGED 80 | ONCOLOGY | RITUXIMAB | VINCRISTINE | CEOP | HEMATOLOGY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Heart Diseases - prevention & control | Male | Epirubicin - administration & dosage | Matched-Pair Analysis | Aged, 80 and over | Vincristine - administration & dosage | Female | Retrospective Studies | Heart Diseases - chemically induced | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Kaplan-Meier Estimate | Etoposide - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Aged | Drug Substitution | Doxorubicin - adverse effects | Epirubicin - adverse effects | Executives | Care and treatment | Anthracyclines | Analysis | Etoposide | Aged patients | Lymphomas | Elderly people | Heart | Therapy | Complications | Medical treatment | Medical services | Feasibility studies | Risk analysis | Disease control | Survival | Doxorubicin | Lymphoma | Patients | Coronary artery disease | Risk factors | Anthracycline | Lymphocytes B | Epirubicin | Heart diseases | Elderly | Geriatrics | Index Medicus
Journal Article
Disease Markers, ISSN 0278-0240, 2017, Volume 2017, pp. 9805609 - 8
Journal Article
Histopathology, ISSN 0309-0167, 01/2013, Volume 62, Issue 2, pp. 326 - 333
Journal Article
European Journal of Haematology, ISSN 0902-4441, 12/2010, Volume 85, Issue 6, pp. 463 - 471
Journal Article